Welcome to our dedicated page for Evaxion AS SEC filings (Ticker: EVAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
When a company’s own research engines are called PIONEER and EDEN, you can expect equally sophisticated disclosures. Evaxion Biotech’s SEC reports are packed with clinical-trial protocols, AI-driven pipeline metrics, and funding milestones that move the share price overnight. For most investors, separating breakthrough data from biotech jargon in a 300-page filing feels impossible.
Stock Titan solves that problem. Our AI reads every new document the moment it hits EDGAR and delivers Evaxion Biotech SEC filings explained simply. Whether you search for “Evaxion Biotech quarterly earnings report 10-Q filing” or need the latest “Evaxion Biotech 8-K material events explained,” you’ll find a clean summary, highlighted risk factors, and direct links to the relevant tables and footnotes.
Wondering what executives do before a big readout? Monitor Evaxion Biotech insider trading Form 4 transactions in real-time and review historical “Evaxion Biotech executive stock transactions Form 4” with one click. Preparing a valuation model? Compare R&D spend and cash runway through the “Evaxion Biotech annual report 10-K simplified.” Curious about board pay? The Evaxion Biotech proxy statement executive compensation section is extracted and translated into plain language. Each report also includes an Evaxion Biotech earnings report filing analysis that calls out revenue recognition changes, trial expense shifts, and partner milestones.
- AI-powered summaries and red-flag alerts
- Real-time “Evaxion Biotech Form 4 insider transactions” feeds
- Side-by-side trends across 10-Q, 10-K and 8-K forms
- Instant keyword search across every exhibit
Stop paging through dense biotech language—start understanding Evaxion Biotech SEC documents with AI and make timely, informed decisions.
Evaxion A/S has filed an F-1 to register up to 38,450,000 ordinary shares, represented by 769,000 ADSs, for resale by the European Investment Bank following a debt-for-warrants settlement.
The registered shares are issuable upon exercise of EIB warrants at DKK 0.25 per ordinary share; Evaxion already obtained cancellation of €3.5 million of EIB debt and may receive up to DKK 9,612,500 (about $1.5 million) if the warrants are fully exercised.
Evaxion is a clinical-stage AI-immunology vaccine developer, with 2024 revenue of $3.3 million and a net loss of $10.6 million, and reported cash and cash equivalents of $10.6 million and total equity of $16.6 million as of September 30, 2025.
Evaxion A/S, a clinical-stage TechBio company focused on AI-Immunology™ powered vaccines, submitted a Form 6-K to furnish a new press release to investors. The press release, dated November 20, 2025, is titled "Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1" and is included as Exhibit 99.1. The company also states that this report is incorporated by reference into several existing registration statements on Forms S-8, F-3 and F-1.
Evaxion A/S reports an amendment to its Articles of Association following the exercise of certain investor warrants. On November 4, 2025, the company registered a share capital increase of nominal DKK 468,750 with the Danish Business Authority, bringing its total share capital to nominal DKK 104,252,689. This increase reflects the issuance of 1,875,000 new ordinary shares in exchange for cash consideration of USD 101,625, which is approximately DKK 659,109.26 based on the USD-DKK exchange rate on that date. The updated Articles of Association reflecting this higher share capital are attached as an exhibit and this report is incorporated by reference into several of Evaxion’s existing registration statements.
Evaxion A/S furnished a Form 6-K announcing that it provided a press release titled “Evaxion announce 2026 financial calendar.” The report is incorporated by reference into the company’s existing registration statements on Form S-8, multiple Form F-1 files, and Form F-3 files, allowing the press release to form part of those registrations going forward. The press release is attached as Exhibit 99.1.
Evaxion A/S furnished a Form 6-K that provides a company press release titled “Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01.”
The filing states that this report is incorporated by reference into Evaxion’s effective registration statements on Forms S-8, F-3, and F-1, making the press release part of those offerings’ prospectuses to the extent not later superseded.
Evaxion A/S furnished a Form 6-K announcing a press release titled “Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate.” The company describes itself as a clinical-stage TechBio firm developing AI-Immunology powered vaccines. The press release, dated November 3, 2025, is included as Exhibit 99.1. This report is also incorporated by reference into Evaxion’s existing registration statements on Forms S-8, F-3, and F-1, making the 6-K part of those filings moving forward.
Evaxion A/S (EVAX) filed an amended Form 6-K to correct a prior press release. The amendment confirms the company will announce its business update and third quarter 2025 financial results on November 6, 2025.
The report states the corrected press release is furnished as Exhibit 99.1 and is incorporated by reference into Evaxion’s effective registration statements on Forms S-8, F-3, and F-1. No financial results or guidance are included in this update.
Evaxion A/S filed a Form 6-K and furnished a press release announcing a business update and third quarter 2025 financial results on November 6, 2025. The company describes itself as a clinical-stage TechBio focused on AI-Immunology powered vaccines. The report is incorporated by reference into Evaxion’s registration statements on Form S-8, multiple Form F-1 files, and Form F-3 files as listed.
Evaxion A/S amended its Articles of Association to reflect multiple warrant exercises and related share capital increases. From October 15–28, 2025, the company registered aggregate share capital increases of nominal DKK 4,735,475, raising its total share capital to nominal DKK 103,783,939.
The warrant exercises brought in aggregate cash consideration of DKK 6,665,343 (or approximately USD 1,038,688 based on the October 28, 2025 exchange rate), comprised of DKK 723,450 (or approximately USD 113,143 based on the October 20, 2025 exchange rate) and USD 925,026. Issuances included 2,025,000 ordinary shares on October 15, 6,479,400 on October 16, 5,350,000 on October 17, and additional tranches through October 28, each with stated nominal increases and cash amounts.
FAQ
What is the current stock price of Evaxion AS (EVAX)?
What is the market cap of Evaxion AS (EVAX)?
